Evaluation of the Effect of Haloperidol, Risperidone, and Quetiapine in the Delirium of Cancer Patients

Phase 3

Recruiting

• Conditions: Condition 1: Delirium. Condition 2: Malignancy.; Delirium due to known physiological condition; Malignant (primary) neoplasm, unspecified; C80.1

• Registration Number: IRCT20190404043159N3
• Lead Sponsor: Esfahan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 26 April 2021

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Diagnosis of any Type of End-stage Cancer
Informed Consent of the Patient or Family
More than 18 Years Old
Diagnosis o Delirium Disorder According to DSM-V Criterion

Exclusion Criteria

Presence of Major Neurocognitive Disorder
Contraindication for Consumption of Antipsychotic Medications

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Delirium Score in Intensive Care Delirium Screening Checklist. Timepoint: Before the intervention and daily for up to 7 days after remission. Method of measurement: Intensive Care Delirium Screening Checklist.